Biodexa Pharmaceuticals Raises $10M in Direct Offering
Ticker: BDRX · Form: 6-K · Filed: Jul 19, 2024 · CIK: 1643918
| Field | Detail |
|---|---|
| Company | Biodexa Pharmaceuticals PLC (BDRX) |
| Form Type | 6-K |
| Filed Date | Jul 19, 2024 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0, $0.9399, $0.0001, $1.00, $85,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: capital-raise, offering, pharmaceuticals
TL;DR
Biodexa just raised $10M via direct offering to fund drug development. Expect news soon.
AI Summary
Biodexa Pharmaceuticals PLC announced on July 18, 2024, that it has entered into agreements for a registered direct offering and a concurrent private placement. The company plans to raise gross proceeds of approximately $10.0 million before deducting offering expenses. The offerings are expected to close on or about July 22, 2024.
Why It Matters
This capital raise provides Biodexa with additional funds to advance its pharmaceutical development pipeline, potentially accelerating the progress of its drug candidates.
Risk Assessment
Risk Level: medium — Capital raises can dilute existing shareholders and the success of the company is dependent on the effective use of these funds for drug development.
Key Numbers
- $10.0M — Gross Proceeds (Raised through registered direct offering and concurrent private placement.)
Key Players & Entities
- Biodexa Pharmaceuticals PLC (company) — Registrant
- July 18, 2024 (date) — Date of offering agreements
- $10.0 million (dollar_amount) — Gross proceeds from offering
- July 22, 2024 (date) — Expected closing date
FAQ
What is the purpose of the registered direct offering and concurrent private placement?
The filing indicates these are part of a capital raise for the company, with gross proceeds expected to be approximately $10.0 million.
When were the agreements for the offering entered into?
The agreements were entered into on July 18, 2024.
What are the expected gross proceeds from these offerings?
The company expects to raise approximately $10.0 million in gross proceeds before deducting offering expenses.
When is the expected closing date for these offerings?
The offerings are expected to close on or about July 22, 2024.
What is the company's principal executive office address?
The company's principal executive offices are located at 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom.
Filing Stats: 1,872 words · 7 min read · ~6 pages · Grade level 13.3 · Accepted 2024-07-19 09:03:18
Key Financial Figures
- $0 — S is being sold at an offering price of $0.94, and each Pre-Funded Warrant is bein
- $0.9399 — t is being sold at an offering price of $0.9399. Each ADS represents 400 ordinary share
- $0.0001 — urchase one ADS at an exercise price of $0.0001 per share. The Pre-Funded Warrants are
- $1.00 — e exercisable at an exercise price of US$1.00 per ADS, subject to adjustments for cer
- $85,000 — ngs and an expense allowance of up to US$85,000 for legal fees and other out-of-pocket
- $1.25 — rice of the Placement Agent Warrants is $1.25 and the term of the Placement Agent War
Filing Documents
- s7182406k.htm (6-K) — 31KB
- ex4_1.htm (EX-4.1) — 112KB
- ex4_2.htm (EX-4.2) — 108KB
- ex4_3.htm (EX-4.3) — 113KB
- ex4_4.htm (EX-4.4) — 103KB
- ex5_1.htm (EX-5.1) — 71KB
- ex5_2.htm (EX-5.2) — 11KB
- ex10_1.htm (EX-10.1) — 244KB
- ex10_2.htm (EX-10.2) — 92KB
- ex99_1.htm (EX-99.1) — 19KB
- 0001214659-24-012668.txt ( ) — 904KB
Forward-Looking Statements
Forward-Looking Statements This report on Form 6-K contains forward-looking statements that involve risks and uncertainties, such as statements related to the anticipated closing of the Offerings and the amount of proceeds expected from the Offerings. The risks and uncertainties involved include the Company’s ability to satisfy certain conditions to closing on a timely basis or at all, market conditions, and other risks detailed from time to time in the Company’s periodic reports and other filings with the SEC. You are cautioned not to place undue reliance on forward-looking statements, which are based on the Company’s current expectations and assumptions and speak only as of the date of this report on Form 6-K. The Company does not intend to revise or update any forward-looking statement in this report on Form 6-K as a result of new information, future events or otherwise, except as required by law. SUBMITTED HEREWITH Attached to the Registrant’s Form 6-K filing for the month of July 2024, and incorporated by reference herein, is: Exhibit No. Description 4.1 Form of Series J Warrant. 4.2 Form of Series K Warrant. 4.3 Form of Placement Agent Warrant. 4.4 Form of Pre-Funded Warrant 5.1 Opinion of Brown Rudnick LLP 5.2 Opinion of Mintz, Levin, Cohn, Ferris, Glovsky & Popeo P.C. 10.1 Form of Securities Purchase Agreement, dated as of July 18, 2024, by and between Biodexa Pharmaceuticals PLC and the investors identified on the signature pages thereto.* 10.2 Placement Agency Agreement, dated as of July 18, 2024, by and between Biodexa Pharmaceuticals PLC and Ladenburg Thalmann & Co. Inc. 99.1 Press release dated July 19, 2024. * Non-material schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted schedules and exhibits upon request by the SEC. SIGNATURE Pursuant to the requirements of the Securitie